Lantus Medicare Part D Coverage: How to Get Insulin Glargine Covered in 2026

How the $35 Medicare Insulin Cap Works for Lantus

The Inflation Reduction Act (IRA), signed into law in August 2022, introduced a $35 per month cost-sharing cap on all Medicare-covered insulin products 1. This provision took effect on January 1, 2025 for all Part D enrollees. It applies regardless of whether the beneficiary has met their deductible.

Before the IRA, Medicare Part D enrollees paid an average of $57.33 per month for insulin during the initial coverage period, according to a 2023 analysis by the Kaiser Family Foundation 2. Patients in the coverage gap faced even steeper costs. A 2021 study published in Diabetes Care found that one in four insulin-dependent Medicare beneficiaries reported rationing doses due to cost (N=982) 3.

The cap applies per insulin product per month. If a patient uses Lantus for basal coverage and a rapid-acting insulin for meals, each product is capped independently at $35. Plans cannot impose step therapy, prior authorization, or quantity limits that functionally deny access to at least one insulin glargine product on their formulary.

Which Medicare Part D Plans Cover Lantus Specifically

Not every Part D plan lists brand-name Lantus on its formulary. Many plans prefer a biosimilar glargine product such as Semglee or Rezvoglar because they negotiate lower rebates with manufacturers. The $35 cap still applies to whichever insulin glargine product the plan covers.

The Centers for Medicare & Medicaid Services (CMS) requires each Part D plan to cover at least one insulin product in each dosage form (vial, pen) and each insulin category (rapid, short, intermediate, long-acting) 4. For long-acting basal insulin, plans must cover at least one glargine or degludec option.

To check whether a specific plan covers Lantus by brand name, beneficiaries can use the Medicare Plan Finder at medicare.gov. Enter the drug name, dosage, and ZIP code. The tool shows which plans cover Lantus, which tier it sits on, and the estimated monthly cost (capped at $35). Patients already enrolled in a plan can call the number on the back of their Part D card and ask the pharmacy benefits manager directly.

If a plan covers only a biosimilar and the prescribing physician believes brand Lantus is medically necessary, the patient can file a formulary exception request. Under 42 CFR §423.578, plans must respond to standard exception requests within 72 hours and expedited requests within 24 hours 5.

Lantus vs. Biosimilar Insulin Glargine: What Medicare Beneficiaries Should Know

The FDA has approved three interchangeable or biosimilar insulin glargine products as of 2026. Semglee (insulin glargine-yfgn), manufactured by Viatris, received interchangeable designation in 2021 6. Rezvoglar (insulin glargine-aglr) from Eli Lilly gained biosimilar approval in 2021 as well.

Interchangeable status means pharmacists in most states can substitute Semglee for Lantus at the pharmacy counter without contacting the prescriber. Biosimilar-only products like Rezvoglar may require a new prescription depending on state pharmacy law. Both products contain the same 100 units/mL insulin glargine molecule and have demonstrated equivalent glycemic control.

A 2020 systematic review in The Lancet Diabetes & Endocrinology analyzed 11 randomized controlled trials comparing biosimilar insulin glargine to originator Lantus (N=5,350 total) and found no clinically meaningful differences in HbA1c reduction, hypoglycemia rates, or immunogenicity 7. Mean HbA1c change from baseline was -1.28% for biosimilars versus -1.31% for Lantus (difference: 0.03%, 95% CI: -0.06 to 0.12).

For Medicare patients, the practical difference comes down to formulary placement and device familiarity. Lantus uses the SoloStar pen. Semglee uses a different injector. Patients with dexterity issues or established muscle memory with a particular pen should discuss device preferences with their provider.

How to Get Lantus at the Lowest Possible Cost on Medicare

The $35 cap is the legal maximum, but some beneficiaries may pay even less. Here is how to minimize costs further.

Low-Income Subsidy (Extra Help). Medicare beneficiaries with limited income and resources can apply for Extra Help through the Social Security Administration. In 2026, qualifying individuals pay $0 for generic or preferred insulin and no more than $4.50 for other covered drugs per prescription 8. About 13 million Medicare beneficiaries qualify for some level of LIS, but an estimated 2 to 3 million eligible individuals have not enrolled, per CMS data.

State Pharmaceutical Assistance Programs (SPAPs). Thirty-three states operate SPAPs that supplement Medicare Part D coverage. Programs vary widely. New York's EPIC program, for example, covers Part D premiums and cost-sharing for residents age 65+ with incomes below $75,000 (single) or $100,000 (married) 9.

Part D plan shopping during Open Enrollment. Formularies and premiums change annually. A plan that covered brand Lantus on Tier 2 this year may move it to Tier 3 or remove it next year. The Annual Enrollment Period runs from October 15 through December 7. Reviewing plan options each year can prevent disruptions and keep premiums low.

$2,000 annual out-of-pocket cap. Starting January 2025, the IRA also introduced a $2,000 annual cap on total Part D out-of-pocket spending 1. For patients using multiple medications, this cap may be reached before mid-year, after which all covered drugs cost $0 for the remainder of the plan year.

What About Commercially Insured Patients and the Uninsured?

The $35 cap applies only to Medicare. Commercially insured patients and uninsured individuals face a different pricing environment.

Sanofi offers the Lantus Savings Card for commercially insured patients, which can reduce copays to as low as $0 per prescription for up to 10 pens or 10 vials per fill. Eligibility excludes government-insured patients (Medicare, Medicaid, Tricare, VA) 10. The program has been renewed annually since 2019.

For uninsured patients, Sanofi's Insulins ValYou Savings Program sets the price of Lantus at $35 per month for up to 10 vials or 10 packs of pens. No income verification is required. This program is separate from the Medicare cap and has its own enrollment process through lantus.com.

Dr. Robert Gabbay, Chief Science and Medical Officer at the American Diabetes Association, has stated: "No one should have to ration insulin because of cost. The combination of federal legislation and manufacturer programs has created real pathways to affordable insulin, but patients need to know these options exist and how to access them" 11.

Mark Cuban's Cost Plus Drugs sells insulin glargine (generic) for approximately $30 per vial plus a dispensing fee. Patients without insurance or those in the Part D coverage gap (before the IRA cap took effect) sometimes used these direct-purchase models.

Understanding Insulin Glargine Formulary Tiers and Prior Authorization

Part D formulary tiers determine the base cost-sharing before the $35 cap applies. Common tier structures include Tier 1 (preferred generics, lowest copay), Tier 2 (preferred brands), Tier 3 (non-preferred brands), and specialty tiers for high-cost biologics.

Most Part D plans in 2026 place at least one insulin glargine product on Tier 2. Brand Lantus may sit on Tier 2 or Tier 3 depending on the plan's rebate agreements with Sanofi. Because the $35 cap overrides the tier-based copay calculation for insulin, the tier placement is less financially significant than it used to be. It still matters for formulary access, since plans may require prior authorization or step therapy for non-preferred tier products.

A 2024 analysis by the Medicare Payment Advisory Commission (MedPAC) found that 94% of Part D plans covered at least one insulin glargine product without prior authorization, and 78% covered brand Lantus specifically 12. Step therapy requirements, where present, typically required a trial of biosimilar glargine before brand Lantus would be approved.

If a prescriber determines that a patient needs brand Lantus specifically (due to device preference, allergy to excipients in biosimilar formulations, or documented clinical response), CMS rules require that the plan adjudicate the formulary exception based on medical necessity criteria, not cost alone.

The Inflation Reduction Act's Broader Impact on Insulin Access

The IRA's insulin provisions represent one component of a larger restructuring of Medicare Part D. Alongside the $35 insulin cap, the law eliminated cost-sharing in the catastrophic coverage phase, introduced the $2,000 annual out-of-pocket maximum, and required drug manufacturers to pay rebates to Medicare when prices rise faster than inflation 1.

For insulin specifically, the inflation rebate provision is significant. Lantus list price has increased by over 600% since its 2000 launch, from approximately $35 per vial to over $300 per vial 13. A 2022 study in JAMA Internal Medicine tracked insulin list prices from 2007 to 2021 and found that glargine prices increased at an annualized rate of 11.5%, far exceeding both general inflation and growth in diabetes prevalence (N=14 insulin products analyzed) 14.

Beginning in 2023, if Sanofi raises Lantus prices faster than the Consumer Price Index, the company must pay a rebate to Medicare for the excess increase. This mechanism creates a financial disincentive for future price hikes. In practice, Sanofi has held Lantus list price relatively stable since 2023, and in some channels has reduced the net price.

The Congressional Budget Office estimated the insulin cap would save Medicare beneficiaries approximately $734 million annually and reduce federal spending by $237 million over 10 years through decreased Low-Income Subsidy outlays 15.

Clinical Considerations: Is Lantus the Right Basal Insulin for You?

Insulin glargine remains one of the most prescribed basal insulins worldwide, with over 10 million active prescriptions in the United States as of 2025. The ORIGIN trial (N=12,537), published in the New England Journal of Medicine, demonstrated that early insulin glargine use in patients with dysglycemia or early type 2 diabetes had a neutral effect on cardiovascular outcomes compared to standard care over a median 6.2-year follow-up 16.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington and a leading authority on insulin therapy, has noted: "Glargine changed basal insulin therapy by providing a relatively peakless 24-hour profile. The biosimilars have maintained that profile while creating downward pricing pressure that benefits patients across all payer types" 17.

For patients on Medicare, choosing between Lantus and a biosimilar should involve three considerations. First, confirm which products your specific Part D plan covers and at what tier. Second, discuss pen device handling with your pharmacist, especially if you have arthritis or neuropathy in your hands. Third, if you are stable on brand Lantus with good glycemic control, switching to a biosimilar for cost reasons is less compelling now that the $35 cap exists across all covered insulin products.

Patients using Lantus should have HbA1c checked at minimum every six months and fasting glucose monitored regularly. The American Diabetes Association recommends an HbA1c target of <7% for most non-pregnant adults, with individualization based on age, comorbidities, and hypoglycemia risk 18.

How to Switch Part D Plans to Get Better Lantus Coverage

Medicare beneficiaries can change Part D plans once per year during the Annual Enrollment Period (October 15 through December 7). Certain qualifying events allow Special Enrollment Periods outside this window: moving to a new service area, losing other creditable drug coverage, qualifying for Extra Help, or being enrolled in a plan that is leaving the Medicare program.

To compare plans, use Medicare Plan Finder (medicare.gov/plan-compare). Enter each medication you take, select your preferred pharmacies, and the tool will rank plans by estimated annual cost. Because the $35 cap applies to all plans, the meaningful differences for insulin users are premiums, coverage of non-insulin medications, and pharmacy network breadth.

Beneficiaries who receive insulin through a Medicare Part B benefit (those using insulin pumps covered under durable medical equipment) are not subject to Part D tier placement. Part B covers insulin and supplies for pump users at 80% after the annual deductible, with no $35 cap, though the $2,000 Part D out-of-pocket maximum does not apply to Part B spending either.

For patients who fill Lantus through a mail-order pharmacy, many Part D plans offer 90-day supplies. The $35 cap applies per month's supply, so a 90-day fill would cost no more than $105.